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Clonal Persistence and Evolution During a Decade
of Recurrent Melanoma
Ena Wang1, Sonia Voiculescu1, Isabelle C. Le Poole2, Mona El-Gamil3, Xin Li1, Marianna Sabatino1,
Paul F. Robbins3, Brian J. Nickoloff2 and Francesco M. Marincola1,4
A patient with metastatic cutaneous melanoma responsive to immunotherapy experienced several recurrences
over a decade of observation. With each recurrence, biopsies were obtained and cell lines generated. A rare
mutation of the b-catenin gene and an unbalanced methylation of the androgen receptor were documented in
all cell lines. Karyotyping and comparative genomic hybridization identified consistent genetic traits in spite of
divergent phenotypes, suggesting that all the metastases were derived from the same primary tumor, although
they were each probably not derived from the most recent previous metastasis in a sequential manner. Thus,
metastatic melanoma recurs from a common progenitor cell and phenotypic changes occur around a central
core of genetic stability. This observation may bear significance for the development of targeted anticancer
therapies.
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INTRODUCTION
Considerable progress has been made in defining the genetic
elements necessary to create a tumor cell with metastatic
potential (Hahn and Weinberg, 2002). A growing body of
evidence indicates that less than a percent of cancer cells
within a tumor, categorized as cancer stem cells, possess
indefinite potential for self-renewal that drives tumor genesis
(Reya et al., 2001). As cancers evolve, novel phenotypes
molded by cumulative genetic alterations continuously
emerge from the progenitor cell to adapt for survival in a
given environment, whereas the cancer stem cells remain
relatively stable and retain the capability for self-renewal and
metastatization. It remains, however, unclear whether
disease recurrences originate from genetically unrelated
clones differently affected by the previous treatment, or a
single cancer stem clone that survives treatment and
perpetuates the disease (Reya et al., 2001; Glinsky et al.,
2005). This distinction has critical implications for anticancer
therapies targeting tumorigenic mutations likely to be more
consistently found in cancer of clonal derivation.
This study provided an opportunity to evaluate the genetic
characteristics of cell lines established from different recur-
rences of cutaneous melanoma arising in the same patient
over more than a decade. The identification of genetic
relatedness among the cultured cells provides evidence for a
clonogenic origin of cutaneous melanoma.
RESULTS
Case report
In December 1988, patient 888 noted that a congenital mole
of the right arm started bleeding. Excisional biopsy revealed
an ulcerated, Clark’s level 5, Breslow thickness 14 mm
melanoma. Concomitant right axillary dissection revealed
that two of 30 assessed lymph nodes were infiltrated with
melanoma cells. In the spring of 1989, the patient experi-
enced multiple visceral and subcutaneous recurrences, and
in June 1989, she received the combined administration
of IL-2 and tumor-infiltrating lymphocytes (TIL 888), which
resulted in a complete regression of all metastases. A cell line
(888-MEL) was generated from the same tumor (Table 1). In
October 1992, the patient experienced a pelvic recurrence
that was partially resected for TIL harvest (TIL 1290). A tumor
cell line was also generated (1290-MEL). Treatment of the
residual pelvic tumor with IL-2 and a combination of TIL 888
and TIL 1290 resulted in a second complete response
(Robbins et al., 1995). TIL 1290 was polyclonal and
recognized several antigens including a mutated domain of
b-catenin (TCT-TTT change responsible for a Ser37-Phe37
substitution). This mutation was also found in 888-MEL
(Rubinfeld et al., 1997) and in a subcutaneous recurrence
excised in June 1995 from which a cell line could not be
generated. In April 2000, the patient experienced a recur-
rence in the right flank treated unsuccessfully with a
b-catenin-reactive clone. The non-regressing mass was
See related commentary on page 1215ORIGINAL ARTICLE
1372 Journal of Investigative Dermatology (2006), Volume 126 & 2006 The Society for Investigative Dermatology
Received 6 October 2005; revised 7 December 2005; accepted 22 December
2005; published online 9 February 2006
1Immunogenetics Section, Department of Transfusion Medicine, Clinical
Center, National Institutes of Health, Bethesda, Maryland, USA; 2Skin Disease
Research Program, Loyola University, Chicago Medical Center, Maywood,
Illinois, USA; 3Surgery Branch, National Cancer Institute, National Institutes
of Health, Bethesda, Maryland, USA and 4James Graham Brown Cancer
Center, University of Louisville, Louisville, Kentucky, USA
Correspondence: Dr. Francesco M. Marincola, Immunogenetics Section,
Department of Transfusion Medicine, Clinical Center, National Institutes of
Health, Building 10, Room 1C-711, 10 Center Drive MSC 1502, Bethesda,
Maryland 20892-1502, USA. E-mail: FMarincola@mail.cc.nih.gov
Abbreviations: CGH, comparative genomic hybridization;
TIL, tumor-infiltrating lymphocyte
resected in September 2000 and independently generated
cell lines (1858-MEL) displayed a heterogeneous phenotype,
but retained the b-catenin mutation; two cell lines expressed
tyrosinase minimally and were poorly pigmented (1858-MEL
b and c), whereas a third (1858-MEL a) maintained the
original pigmentation and expressed tyrosinase. In June 2001,
the disease became rapidly progressive and unresponsive to
therapy with a recurrence in the right chest wall followed by
another in the right breast. In both occasions, cell lines could
be generated (1936-MEL and 1962-MEL, respectively), which
displayed the same b-catenin mutation.
Genetic testing
As the patient was a female, it was possible to apply the
human androgen receptor assay (HUMARA) to test whether
the same allele was exclusively methylated (Rabkin et al.,
1997). In spite of strikingly different phenotypic character-
istics as exemplified by the lack or presence of pigmentation
(Figure 1a), all cell lines displayed an identical methylation
pattern (Figure 1b). Karyotyping revealed a dramatic level of
instability in the original 888-MEL cell line with a high
percentage of pseudo-tetraploid cells (16 of 25 metaphases
analyzed; Table 2). Common aberrations included loss of
normal copies of chromosomes 10, 11, 14, 16, and 18.
A gain of chromosome 20 was seen in the majority of
cells. Several marker chromosomes were present particularly
involving chromosomes 3, 7, and 17, which were present
in all subsequent cell lines. Cell line 1290-MEL appeared
more stable (six of 24 tetraploid metaphases). Consistent
chromosomal aberrations included loss of chromosomes 10,
11, 16, 17, and 18 and loss of 14 in six of 14 metaphases
analyzed. Cell line 1858-MEL was the most stable with a
near-diploid karyotype (two of 18 tetraploid metaphases).
There were consistent telomere deletions of chromosomes
9p and 10p. One copy of chromosomes 14, 16, 17, and 18
was lost. A dramatic change occurred in 1936-MEL, which
was highly unstable with almost all metaphases analyzed
been triploid or near tetraploid (10 of 12 metaphases).
Because of the many rearrangements, a detailed karyo-
type analysis could not be performed. Still, several
chromosomal imbalances typical of the previous stage could
be observed including loss of chromosomes 10, 14, 17, and
18. The final cell line 1962 showed a reduced karyotypic
complexity retaining, however, changes consistent with
the previous cell lines including loss of chromosomes 10,
14, 16, 17, and 18. The different ploidy pattern of each
cell line is commonly observed in vitro representing a marker
of chromosomal instability, whereas chromosomal dele-
tions are a more robust marker of clonal derivation (Roschke
et al., 2003).
In heterogeneous cell populations, karyotyping gives a
limited view of a tumor as a whole as it selectively analyzes a
small cell sample. Comparative genomic hybridization
(CGH), therefore, was performed to provide a global view
of the genomic imbalances present in the majority of cells,
although it may miss some deletions in conditions in high
ploidy (Table 3). The original 888-MEL cell line demonstrated
a high number of chromosomal imbalances. Cell line 1290-
MEL retained the 10, 17p, þ 17q pattern observed in 888-
MEL and demonstrated novel aberration including þ3p, þ 7,
which were retained in the subsequent cell lines supporting
their common origin. Although CGH and karyotyping results
did not perfectly match, a good correlation was noted
between the two assays regarding the common imbalances
involving þ3, þ7, 10, and 17 with the presence of
marker chromosomes 3 and 7 by karyotyping of nearly
diploid cell lines and consistent identification of chromo-
somes 10 and 17 deletions by both assays. Hierarchal
clustering identified a cluster of genetic imbalances common
to most cell lines that could be consistently observed also by
karyotyping (red line box; Figure 1c). This cluster included
þ 3, þ 7, 10p, 17, and þ17q, suggesting that these
imbalances represent those directly inherited by a common
progenitor clone. In general, both assays suggested that while
some genetic changes were shared by all of the cell lines, not
all the changes were retained. This observation raises the
possibility that while all the metastases are derived from the
same primary ancestor, they were each probably not derived
from the most recent previous metastasis in a sequential
manner.
Table 1. Time and site of biopsies in patient 888
Cell line name Date of biopsy Source
Not done December 1988 Primary melanoma, right arm
888-MEL 21 June 1989 Subcutaneous, soft palate
1290-MEL p14 6 October 19920 Uterine metastasis
1290-MEL p54 6 October 1992 Uterine metastasis
1858-MEL a (Fragment) 30 September 2000 Subcutaneous, R flank
1858-MEL b (Medimachine) 30 September 2000 Subcutaneous, R flank
1858-MEL c (Wash) 30 September 2000 Subcutaneous, R flank
1936-MEL (Medimachine) 13 June 2001 Subcutaneous, R chest wall
1962-MEL 28 August 2001 Subcutaneous, R breast
R flank=right flank.
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DISCUSSION
It is generally accepted that the natural history of cancer is
determined by the clonal expansion of a single progenitor
cell transformed at the origin of the oncogenic process
(Sidransky, 1995; Bevilacqua et al., 1998). From this
common ancestor, descendants multiply and migrate causing
the insurgence of multifocal synchronous or metachronous
tumors. This theory is supported by the identification in the
descendants of shared genetic traits inherited from the
common ancestor around whom additional genomic altera-
tions may progressively arise. In contrast to the clonogenic
theory, the field change theory postulates that a global
alteration induced by unusual biological circumstances
affects an exposed tissue (Soto and Sonnenschein, 2004).
This may initiate the parallel transformation of multiple cells
that independently mold the natural history of the disease.
Whereas most animal models, however, support a strictly
clonogenic progression of experimental cancers (Iannaccone
et al., 1987), in humans very few studies addressed this
question as long-term survival of patients with recurrent
metastatic cancer is exceedingly rare. Indeed, clonal progres-
sion of primary cutaneous melanoma from the radial to
the vertical growth phase has been demonstrated by CGH
(Wiltshire et al., 1995; Bastian et al., 1998). In addition,
clonality of in transit melanoma metastases could be
demonstrated by loss of heterozygosity analysis (Wiltshire
et al., 2001), whereas comparison of primary tumor and
metastases from the same patients identified consistent
chromosomal imbalances revealed by CGH (Balazs et al.,
2001). Thus, these and other studies convincingly established
the clonal relationship between primary tumors and subse-
quent metastases. However, a long-term analysis such as the
one permitted by the unusual history of the patient described
here who survived several recurrences over an unusually
protracted period of time after the first metastatic event has
never been reported. In fact, reports are limited to cases of
lymphomatoid papulosis and related lymphomas in which
clonality could be assessed by T cell receptor rearrangement
analysis over a long time span (Amagai et al., 1995). Whether
these findings could be extrapolated to other more common
cancers remains unclear; yet this information is critical because
clonal derivation may affect the feasibility of anticancer
therapies targeting genetic aberrations specific for cancers.
In this study, the metastatic pattern of melanoma could be
followed over an unusually long period of time in which
several recurrences at distant sites amplified the chances of
identifying divergent genotypic and phenotypic characteristic
in the tumor cells. The findings strongly support a clonal
derivation of all metastatic recurrences in this patient. As the
study was based on cell lines derived from the different
metastases, part of the information related to the whole
tumors might be missed. Yet, cell lines should be representa-
tive of persistent genetic alterations in vivo as converging
genotypes are unlikely to randomly occur in vitro (Vogl
et al., 2005) under steady-state culture conditions where only
limited karyotypic evolution occurs even in the presence of
extensive chromosomal instability (Roschke et al., 2002). In
fact, prominent karyotype features may be maintained
throughout years of continuous culture in spite of observable
karyotypic heterogeneity at any given time point (Macville
et al., 1999; Masramon et al., 2000; Kawai et al., 2002). In
addition, others have shown that a correlation exists between
genetic aberrations observed in cell culture and those
identifiable in primary tumors (Roschke et al., 2003). For
instance, a survey of the NCI-60 cancer cell line panel
demonstrated extreme karyotypic variability within each cell
line that involved ploidy, numerical, and structural hetero-
geneity (Roschke et al., 2003). Yet, within such variability,
constant karyotypic characteristics were maintained that
could be recounted in the primary tumors.
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Figure 1. (a) Pigmentation in vitro of six cell lines derived from patient 888
(Table 1) and (b) methylation pattern of the human androgen receptor assay
(HUMARA). The pattern is present in the absence () or presence (þ ) of
digestion with the methylation-sensitive restriction endonuclease HpaII.
Undigested DNA demonstrates the two allelic variants of the gene, whereas
unbalance mutilation is consistently seen in all cell lines with only one allele
consistently protected from digestion by methylation. (c) Linkage clustering
among distinct genomic imbalances based on the binary, Euclidean distance
comparing individual cell lines. The red line box includes the primary cluster
of imbalances likely to represent the imbalances displayed by the founder
clone (see text).
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Several lessons can be derived from this study. First, from
the initial clinical presentation of metastatic disease, the
cultured melanoma cells expanded in vitro contained genetic
abnormalities that persisted throughout the natural disease
process. Second, while repeated administrations of immuno-
therapy induced complete remissions, these clinical res-
ponses were followed by relapses, and melanoma cells
isolated from lesions following initial remission/relapses
were clonally related to the original lesion. This suggests
that treatment recurrence is not owing to the emergence of
separate tumor clones, but rather to mutants evolving from
the same ancestor. Third, despite being nearly genetically
Table 2. Detailed karyotype analysis of close to diploid cell lines
Id (ploidy) m Karyotype Marker chromosomes
888-MEL (16/25) 1 47, XX, 10, 11, dup (12q), 14, 16, 18, 19, +20, +mar (6) 3p, 3q, 7q, 10, 14, 17
2 47, XX, 10, 11, dup (12q), 14, 16, 18, +20, +mar (5) 3p, 3q, 7q, 10, 17
3 47, XX, 10, 11, dup (12q), 14, 16, 18, 19, +20, +mar (6) 3, 7q, 10, 14, 16, 17
4 47, XX, 10, 11, dup (12q), 14, 16, 18, 19, +20, +mar (6) 3p, 3q, 7q, 10, 14, 17
5 48, XX, +1, 10, 11, 12, 14, 16, mar (6) 3p, 7, 10, 14, 17
1290-MEL (6/24) 1 47, XX, de (1), del (6), del (9p), 10, 11, 16, 17, iso (17q), 18, +mar (6) 3p, 7, 12q, 17
2 44, XX, 10, 12, 14, 15, 16, 17, iso 17q, 18, +mar (4) 3p
3 45, XX, 8, 9, 10, 11, 14, 15, 16, 17, iso (17q), +mar (7) 3p, 7
4 48, XX, 3, ctb (5q), 6, 9, 11, 16, 17, iso (17q), 18, +19, +20, +mar (6) ins (2), 3, 7, 12
5 47, XX, del (6), 9p, 10, 11, 16, 17, iso (17q), 18, +19, +21, +mar (5) 3, 7,
6 47, XX, 9, 11, 16, 17, iso (17q), 18, +19, +mar (4) 7
8 46, XX, 3, 6, 10, 11, 13, 15, 16, 17, iso (17q), 18, +mar (7) 3, 6p, 7, rob (13;15)
10 47, XX, 6, 9, 10, 11, 13, 17, 18 +mar (7) 3p, 6, 7, 13, 17
11 42, XX, 5, ctb (6p), 9, del (10p), 11, 12, 14, 16, ctb (16q), 17, 18, 7, 11, 12, 14, 17
12 46, XX, 6, 10, 11, 14, 16, 17, iso (17q), 18, +mar (6) 6, 7, 10, 11,
13 46, XX, +4, 6, del (9p), 10, 11, 14, 16, 17, 18, +mar (6) 3p, 6, 7, 11, 17
14 45, XX, 6, del (9p), 10, 11, 14, 16, 17, 18, +mar (6) 6, 7, 11, 17
1858-MEL (2/18) 1 46, X, 14, 16, 17, 18, +20, X, +mar (5) 3p, 10, 17, X
2 48, X, ctb (1), +2, 7, del (9p), del (10p), 14, 16, 17, X, +mar (6) 3p, 7, 17
3 46, X, ctb (p), 7, del (9p), del (10p), 14, 16, 17, 18, X, +mar (6) 3p, 7, 17, X
4 46, X, del (2), 7, del (9p), del (10p), 16, 17, 18, X, +mar (5) 3p, 7, 17, X
5 45, XX, ctb (1p), 6, 7, 8, del (9p), del (10), ctb (14q), 15, 16, 17, 18, +21 +mar (5) 3p, 6, 7
6 46, X, 8, del (9p), del (10), 14, 16, 17, 18, +mar (6) 3p, 7, 17, X
7 46, X, 8, 10, ctb (12q), 14, 16, 17, 18, del (21), X, +mar (7) 3p, 17, X
8 46, X, 2, 3, del (9p), del (10p), 16, 17, 18, 21 X, +mar (7) 3p, 7, 17, X
9 45, X, 8, del (9p), del (10p), 14, 16, 17, 18, +20, 22, X, +mar (5) 3p, 7, 17, X
10 47, X, 8, del (9p), del (10p), 12, 14, 16, 17, X, +mar (7) 3p, 7, 17, X
11 48, XX, 7, 8, del (9p), 10, del (13q), 14, 16, 17, 18, +20, +mar (8) 3p, 7, 14, 17
12 46, X, +3, 8, del (9p), del (10p), 17, 18, X 17, X
13 45, X, 8, del (9p), del (10p), 14, 16, 17, 18, X, +mar (5) 3, 7, 8, 17, X
1936-MEL (10/12) Not done (most metaphases either triploid or tetraploid)
1962-MEL (9/25) 1 44, X,  8, 9, 14, 16, 17, 18, 20, X, +mar (6) 7, 17, X
2 46, XX, +5, 10, 11, 16, 17, 18, +mar (4)
3 48, X, +2, 9, 10, 14, 16, 17, 20, X, +mar (8) 3p, 10, 17, X
4 45, X,  4, 9, 11, 14, 16, 17, 18, del (X), X, +mar (7) 3p, 7, 17, X
5 46, X, +1, 9, 10, 14, 16, 17, 18, X, +mar (6) 3p, 7, 10, 17
6 47, X, +2, 9, del (10p), 14, 16, 17, 18, X, +mar (6) 3p, 7, 14, 17, X
Ctb=chromatid break; Del=deleted; Dup=duplication; Iso=iso chromosome; Mar=marker chromosome; Rob=Robertsonian translocation.
Summary of karyotyping results in cell lines with a nearly diploid chromosome number. Results of several metaphases (m) are shown. The column ‘‘id
(ploidy)’’ refers to the name of the cell line and in parentheses is shown the number of metaphases in which chromosome counts were close to tetraploid.
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identical, the clones of melanoma displayed in vitro diverse
phenotypic characteristics such as being pigmented or non-
pigmented, suggesting that dramatically different phenotypes
can derive from genetically related precursor cells. Fourth,
after almost a decade of clinical responses/relapses, a sub-
clone emerged that was still genetically close to the previous
cells, but acquired a phenotype refractory to immunotherapy.
We conclude that several chromosomal abnormalities that
were present in the original metastatic lesion were necessary
and sufficient to create fully evolved malignant cells with
metastatic behavior, and a clone of melanoma cells persisted
for many years slowly evolving into a therapy-refractory
phenotype that acquired treatment resistance. The persistent
mutation in b-catenin could indicate activation of stem cell-
like signaling pathways that may contribute to the biological
behavior of this patient tumor. This mutation stabilizes
b-cateninin–Lef-1 complexes constitutively activating self-
renewal properties (Reya and Clevers, 2005) independently
of wnt signaling (Rubinfeld et al., 1997) necessary for normal
stem cell self-perpetuation (Reya and Clevers, 2005). A
previous analysis identified mutations in this gene in eight of
26 melanoma cell lines and the exact was present only in
four, of which two (888-MEL and 1290-MEL) were derived
from this patient (Rubinfeld et al., 1997). The relative rarity of
this mutation suggests that it is unlikely that it occurred
randomly in genetically unrelated clones.
Whether addition of genotoxic agents would have
hastened the genomic instability process that appeared to
be delayed for many years in this patient is unknown. Future
studies are warranted to determine if immunotherapy in
selected patients with tumors bearing distinct genotypic
abnormalities and proapoptotic/senescent vulnerabilities
may be a preferred treatment so as to minimize genomic
instability and emergence of more biologically aggressive
clones.
MATERIALS AND METHODS
Cell expansion, culture, and human leukocyte antigen typing
Melanoma cell lines were generated at the Surgery Branch, National
Cancer Institute (Bethesda, MD), except for A375 purchased from
the American Type Culture Collection (Rockville, MD). Cell lines
were maintained in steady-state culture conditions using RPMI
(Biosource International, Camarillo, CA) supplemented with 10%
fetal calf serum (Biosource) and harvested by Trypsin/Versene
(Biosource) digestion (Cormier et al., 1999). To exclude experi-
mental switching or contamination, the human leukocyte antigen
type of each cell lines was confirmed by sequence-specific primer
PCR (Player et al., 1996). All experiments were conducted under
institutional approval.
Genetic testing
The methylation pattern of the human androgen receptor gene
(HUMARA) was assayed as reported previously (Rabkin et al., 1997).
Karyotyping and chromosomal CGH were performed by Concentric
Labs (Potomac, MD). G-band karyotyping was performed in a
standard manner according to a previously described procedure
(Verma and Babu, 1995). Cells were treated for 10–15 minutes in
0.075 M KCl hytopotonic solution, followed by fixation in 3:1
methanol:acetic acid. At least 20 cells were karyotyped. Genomic
DNA for CGH was labeled with either digoxigenin-11-deoxy uridine
triphosphate (normal DNA) or biotin-16-deoxy uridine triphosphate
(tumor DNA) by nick translation reaction (Boehringer Mannheim,
Indianapolis, IN). Equal amounts of normal and tumor DNA were
hybridized at 371C for 72 hours to metaphase spreads prepared from
normal cultured lymphocytes (Agarwal et al., 1998). The biotiny-
lated sequences were detected with FITC-conjugated avidin (Vector,
Burlingame, CA), and digoxigenin-labeled sequences by mouse anti-
digoxigenin antibody, followed by tetramethylrhodamine isothio-
cyanate-conjugated goat anti-mouse antibody. Chromosomes were
counterstained with 4,6-diamidino-2-phenylindole. Image acquisi-
tion was carried out using Leica Q-FISH imaging software and ratio
profiles calculated using Leica Chantal software (Leica Imaging
Systems, Cambridge, UK). b-Catenin mutations were documented by
sequencing (Rubinfeld et al., 1997). Finally, relation between
chromosomal imbalances was analyzed testing the binary Euclidian
distance of each imbalance among cell lines based on the average
linkage between groups.
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Table 3. Summary of comparative genomic hybridization results
No. Chromosomal imbalances Ploidy
888 6qter, 9, 10, +11p, +12q, 14q, 17p, +17q, +20q 16/25 near tetraploid
1290 +3p14–23, +6pter-q23, +7, 10p, 11q23-qter, +15, 17p, +17q, 18p, +19 6/24 near tetraploid
1858 +3p, +7, 8p, 9p, 10p14, 17p, +17q 2/18 near tetraploid
1936 +1q, +3p, 4q32-qter, +5, +7, 10p14–pter, 11q21-qter, 13q, 14q32-qter, +15, +16,
17p, +17q, 18, +20q, 21
10/12 near triploid/tetraploid
1962 +3p, 5p, +7, 8p, 9p, 10p15, 14q32, 16q, 17p, +17q, 20p 9/25 near tetraploid
Flow chart of the karyotypic transitions from one cell line to the next based on chromosomal hybridization results. Consistent changes present in all cell lines
are designated in bold and unique changes (different from the previous stage) are in italics. Ploidy is derived by karyotyping results of distinct cells
metaphases.
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